BRIEF-Pfizer Announces Tafamidis Phase 3 ATTR-ACT Study Met Its Primary Endpoint

1 分钟阅读

March 29 (Reuters) - Pfizer Inc:

* PFIZER ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ATTR-ACT STUDY OF TAFAMIDIS IN PATIENTS WITH TRANSTHYRETIN CARDIOMYOPATHY

* PFIZER INC - STUDY MET ITS PRIMARY ENDPOINT

* PFIZER INC - PRELIMINARY SAFETY DATA SHOWED THAT TAFAMIDIS WAS GENERALLY WELL TOLERATED

* PFIZER INC - PRELIMINARY SAFETY DATA SHOWED THAT TAFAMIDIS WAS GENERALLY WELL TOLERATED IN POPULATION AND NO NEW SAFETY SIGNALS WERE IDENTIFIED Source text for Eikon: Further company coverage:

我们的标准：汤森路透“信任原则”

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below